Categories: Wire Stories

AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer�s Disease Phase 2 Study at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD� 2023)

SAN DIEGO–(BUSINESS WIRE)–AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer�s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.

The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.

Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.

AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.

About AR1001-ADP3-US01

AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer’s disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.

About AriBio

AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.

Contacts

James Rock jimrock@aribiousa.com
AriBio USA Branch

Alex

Recent Posts

Zhengzhou: Interactive Exhibitions on the International Museum Day

ZHENGZHOU, China--(BUSINESS WIRE)--In central China’s Zhengzhou city, visiting museums has become a new trend of…

9 mins ago

Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally

Mollie Pearce, star of the UK reality TV show ‘The Traitors’ who was diagnosed with…

10 hours ago

Quality Building Award 2024 Unveils Finalist List

QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…

2 days ago

UXLINK Tops RootData’s Latest X Hot Items List and DappRadar Social Apps List

SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…

2 days ago

Australia Construction Industry Report 2024: Growth to Slow to 2% in Real-terms this Year Following 9% Growth in 2023 – Forecasts to 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…

2 days ago

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…

2 days ago